Evidence map›Paper›PMID 34976813›Full record

ArticleFrontiers in oncology2021

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination

Lin Wu, Chao Deng, Hui Zhang, Jie Weng, Youhua Wu, Shan Zeng, Tiegang Tang, Peiguo Cao, Bo Qiu, Li Zhang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Lin WuDepartment of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China.
Chao DengDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
Hui ZhangDepartment of Oncology, The Central Hospital of Shaoyang, Shaoyang, China.
Jie WengDepartment of Oncology, The First People's Hospital of Yueyang, Yueyang, China.
Youhua WuDepartment of Oncology, The First Affiliated Hospital of South China University, Hengyang, China.
Shan ZengDepartment of Oncology, The Xiangya Hospital of Central South University, Changsha, China.
Tiegang TangDepartment of Oncology, The Central Hospital of Xiangtan, Xiangtan, China.
Peiguo CaoDepartment of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China.
Bo QiuDepartment of Oncology, The Central Hospital of Zhuzhou, Zhuzhou, China.
Li ZhangDepartment of Oncology, Peking Union Medical College Hospital, Beijing, China.
Huaxin DuanDepartment of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Bing ZhangDepartment of Oncology, The Central Hospital of Yiyang, Yiyang, China.
Dong ZhangDepartment of Oncology, Chinese PLA General Hospital, Beijing, China.
Taotao ZhangGuizhou Jinqiao Pharmaceutical Co., Ltd., Guiyang, China.
Chunhong HuDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese PLA General Hospital · CNGuizhou Magic Pharmaceutical (China) · CNHunan Cancer Hospital · CNHunan Normal University · CNThe Central Hospital of Shaoyang · CNUniversity of South China · CNXiangyang Central Hospital · CNYueyang Second People's Hospital · CNZhuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second-line treatment options for advanced/metastatic non-small cell lung cancer (NSCLC) patients are limited. We aimed to evaluate the efficacy and safety of docetaxel/sodium cantharidinate combination

Indexed as

combinationdocetaxel (DOC)efficacy and safetynon-small cell lung cancersodium cantharidinate

Identifiers

PMID34976813
PMCPMC8715707
OpenAlexW4200351766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.